Trevor J. Powles

Q: What Schools Are Affiliated With Trevor J. Powles

Trevor J. Powles is affiliated with the following schools: University of Calgary, Institute of Cancer Research, University of Sussex, University of Sheffield, Royal Postgraduate Medical School

Trevor J. Powles's AcademicInfluence.com Rankings

Trevor J. Powles

Medical

#2771

World Rank

#3206

Historical Rank

Oncology

#178

World Rank

#184

Historical Rank

medical Degrees

Trevor J. Powles

Philosophy

#7924

World Rank

#11208

Historical Rank

Logic

#4957

World Rank

#6302

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Trevor J. Powles's Degrees

PhD Oncology University of Oxford
Doctorate Medicine University of Oxford

Why Is Trevor J. Powles Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Trevor J. Powles's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Tamoxifen for early breast cancer: an overview of the randomised trials (1998) (3764)
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. (1999) (1638)
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. (2002) (1006)
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial (1998) (921)
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial (2000) (746)
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. (1996) (650)
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial (2004) (647)
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. (2004) (633)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) (614)
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. (1993) (570)
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial (1994) (491)
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data (2013) (398)
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. (2002) (390)
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. (2007) (379)
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. (1995) (342)
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. (1998) (316)
DETECTION OF MICROMETASTASES IN PATIENTS WITH PRIMARY BREAST CANCER (1983) (263)
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. (1989) (255)
A high incidence of vertebral fracture in women with breast cancer (1999) (255)
Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. (2006) (252)
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. (1987) (232)
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. (1999) (231)
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. (2008) (229)
Clodronate decreases the frequency of skeletal metastases in women with breast cancer. (1996) (227)
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer (2002) (227)
Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. (1986) (226)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] (2006) (191)
The Inhibition by Aspirin and Indomethacin of Osteolytic Tumour Deposits and Hypercalcaemia in Rats with Walker Tumour, and its Possible Application to Human Breast Cancer (1973) (190)
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma (2000) (183)
Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. (1981) (177)
Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. (1987) (173)
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. (2016) (170)
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. (1997) (165)
Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. (1998) (164)
Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. (1996) (160)
Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. (1990) (157)
Lasofoxifene in postmenopausal women with osteoporosis. (2010) (156)
Tamoxifen-Induced Anorexia Is Associated With Fatty Acid Synthase Inhibition in the Ventromedial Nucleus of the Hypothalamus and Accumulation of Malonyl-CoA (2006) (155)
Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment (1998) (152)
Growth factor expression in normal, benign, and malignant breast tissue (1988) (144)
Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancer (1988) (138)
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. (2010) (133)
FAILURE OF CHEMOTHERAPY TO PROLONG SURVIVAL IN A GROUP OF PATIENTS WITH METASTATIC BREAST CANCER (1980) (131)
The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. (1996) (128)
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. (2000) (125)
Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. (2001) (124)
BREAST-CANCER OSTEOLYSIS, BONE METASTASES, AND ANTI-OSTEOLYTIC EFFECT OF ASPIRIN (1976) (122)
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. (2002) (108)
COMMENT ON: TAMOXIFEN FOR PREVENTION OF BREAST CANCER : REPORT OF THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT P-1 STUDY (1999) (108)
Assessment of response of bone metastases to systemic treatment in patients with breast cancer (1983) (108)
32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. (1995) (107)
Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. (1982) (105)
Factors affecting acute skin toxicity in patients having breast irradiation after conservative surgery: a prospective study of treatment practice at the Royal Marsden Hospital. (1996) (103)
Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. (1990) (98)
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. (1992) (97)
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. (1986) (97)
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance (2006) (97)
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women (2011) (96)
The feasibility of using fine needle aspiration from primary breast cancers for cDNA microarray analyses. (2002) (91)
The prognostic significance of transforming growth factors in human breast cancer. (1993) (90)
DETECTION OF BREAST CARCINOMA METASTASES IN BONE: RELATIVE MERITS OF X-RAYS AND SKELETAL SCINTIGRAPHY (1983) (90)
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. (2003) (89)
The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. (1992) (89)
Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] (2006) (86)
AMINOGLUTETHIMIDE IN TREATMENT OF METASTATIC BREAST CARCINOMA (1978) (86)
Hormone replacement after breast cancer (1993) (84)
Non-steroidal anti-inflammatory drugs and cytotoxics. (1979) (84)
Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma (1999) (83)
The case for clinical trials of tamoxifen for prevention of breast cancer (1992) (82)
Comparison of Different Trials of Adjuvant Chemotherapy in Stage II Breast Cancer Using a Natural History Data Base (1987) (82)
PREDICTION OF ENDOCRINE RESPONSE IN BREAST CANCER BY IMMUNOCYTOCHEMICAL DETECTION OF OESTROGEN RECEPTOR IN FINE-NEEDLE ASPIRATES (1987) (79)
Clinical examination, xeromammography, and fine-needle aspiration cytology in diagnosis of breast tumours. (1978) (78)
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. (1991) (77)
The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis (2006) (76)
The role of computed tomography in the detection of bone metastases in breast cancer patients. (1983) (73)
Human breast tumour-induced osteolysis and prostaglandins. (1976) (72)
Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer (2003) (71)
ASSESSMENT OF BIOCHEMICAL TESTS TO SCREEN FOR METASTASES IN PATIENTS WITH BREAST CANCER (1980) (71)
Effects of endocrine therapy on steroid-receptor content of breast cancer. (1982) (71)
The Royal Marsden Hospital pilot tamoxifen chemoprevention trial (2004) (71)
Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response (1998) (70)
Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials (2013) (69)
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. (2005) (67)
p53 protein overexpression and chemosensitivity in breast cancer (1995) (65)
Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study (2004) (64)
Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer (2008) (63)
Tamoxifen for the prevention of breast cancer. (2000) (63)
BIOCHEMICAL MARKERS IN HUMAN BREAST CANCER (1977) (62)
Immunocytochemical assay for estrogen receptor: relationship to outcome of therapy in patients with advanced breast cancer. (1986) (61)
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials (2016) (61)
Clinical studies of apoptosis and proliferation in breast cancer. (1999) (60)
Development and Use of a Natural History Data Base of Breast Cancer Studies (1987) (58)
Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers (1998) (57)
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. (1999) (54)
Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place. (1999) (54)
TAMOXIFEN AND BENIGN BREAST PROBLEMS (1987) (53)
Tamoxifen in the Prevention of Breast Cancer (1994) (53)
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy (2006) (52)
Chemoprevention of breast cancer (1989) (51)
Extended Safety Profile of Oral Clodronate After Long-Term Use in Primary Breast Cancer Patients (2003) (51)
Prostaglandin mediation of collagenase-induced bone resorption (1976) (50)
Effects of tamoxifen on uterus (1994) (49)
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. (1997) (49)
The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. (2004) (47)
Hydroxyproline excretion in patients with breast cancer and response to treatment. (1975) (47)
Anti-oestrogenic prevention of breast cancer — the make or break point (2002) (46)
Breast cancer prevention (1999) (46)
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. (1994) (45)
A biochemical approach to the staging of human breast cancer (1977) (45)
Cytological evaluation of biological prognostic markers from primary breast carcinomas (1997) (44)
In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer. (1986) (44)
Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors. (1978) (44)
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene (2012) (43)
Timing of surgery in breast cancer (1991) (42)
TREATMENT OF DISSEMINATED BREAST CANCER WITH TAMOXIFEN, AMINOGLUTETHIMIDE, HYDROCORTISONE, AND DANAZOL, USED IN COMBINATION OR SEQUENTIALLY (1984) (42)
Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. (1996) (42)
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. (1993) (41)
MENSTRUAL EFFECT ON SURGICAL CURE OF BREAST CANCER (1989) (41)
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. (1992) (40)
Early morning hydroxyproline excretion in patients with breast cancer (1976) (40)
Enhancement of anti-cancer activity of cytotoxic chemotherapy with protection of normal tissues by inhibition of P.G. synthesis. (1978) (39)
Failure of indomethacin to reduce hydroxyproline excretion or hypercalcemia in patients with breast cancer (1976) (39)
15-KETO-13, 14-DIHYDROPROSTAGLANDIN E2 CONCENTRATIONS IN SERUM OF PATIENTS WITH BREAST CANCER (1977) (38)
An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. (1992) (37)
Prognostic significance of micrometastases in bone marrow in patients with primary breast cancer. (1986) (36)
Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. (2010) (35)
Bilateral carcinoma of the breast (1980) (34)
Aspirin inhibition of in vitro osteolysis stimulated by parathyroid hormone and PGE1. (1973) (34)
Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy (2004) (33)
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. (1996) (32)
Comparison of computed tomography and conventional radiology in the assessment of treatment response of lytic bony metastases in patients with carcinoma of the breast. (1987) (32)
Screening for metastases in breast cancer: An assessment of biochemical and physical methods (1981) (32)
PREVENTION OF MIGRAINOUS HEADACHES BY TAMOXIFEN (1986) (31)
Survey of treatment of primary breast cancer in Great Britain. (1985) (31)
Treatment of skeletal disease in breast cancer with clodronate. (1991) (31)
The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients (2004) (30)
Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer (2006) (30)
Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. (1991) (29)
Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference (2006) (29)
Review of a hospital experience of breast abscesses (1989) (29)
Lack of Diurnal-Variation in Plasma-Levels of Androstenedione, Testosterone, Estrone and Estradiol in Postmenopausal Women (1989) (28)
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. (1994) (28)
Breast cancer response to hormone replacement therapy withdrawal (1995) (28)
An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer. (1986) (27)
Chemoprevention options for BRCA1 and BRCA2 mutation carriers. (2000) (27)
Isoflavones and women's health (2004) (26)
Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone. (1982) (26)
Adjuvant treatment in breast cancer (1992) (26)
Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial (2004) (26)
Oral clodronate for adjuvant treatment of operable breast cancer: Results of a randomized, double-blind, placebo-controlled multicenter trial. (2004) (25)
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. (1996) (25)
Estrogen Receptors in Human Breast Cancer (1976) (25)
Use of inhibitors of prostaglandin synthesis in patients with breast cancer. (1980) (24)
An acute toxicity study on the effects of synchronous chemotherapy and radiotherapy in early stage breast cancer after conservative surgery. (1996) (24)
Physical Test for Distant Metastases in Patients with Breast Cancer (1980) (24)
Presurgical determination of estrogen receptor status using immunocytochemically stained fine needle aspirate smears in patients with breast cancer. (1987) (24)
Variation in endometrial thickening in women with amenorrhea on tamoxifen (1998) (23)
Danazol treatment for advanced breast cancer (1980) (23)
Fine Needle Aspiration Cytodiagnosis As A Pre‐Requisite For Primary Medical Treatment of Breast Cancer (1991) (21)
How many tests are required in the diagnosis of palpable breast abnormalities? (1990) (20)
Phase I study of TNFα AutoVaccIne in Patients with metastatic cancer (2005) (20)
Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer. (1982) (20)
Efficacy of tamoxifen as treatment of breast cancer. (1997) (19)
Bilateral carcinoma of the breast. (1980) (19)
Circulating levels of pregnancy specific β1 glycoprotein in patients with testicular, bronchogenic and breast carcinomas (1980) (19)
Tamoxifen therapy and carcinogenic risk. (1995) (19)
A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen (2004) (18)
Mechanisms for development of bone metastases and effects of anti inflammatory drugs (1982) (17)
ORAL CONTRACEPTIVES AND BREAST CANCER (1983) (17)
Combination chemotherapy of metastatic breast cancer with vincristine, adriamycin and prednisolone (1978) (17)
Bone Mineral Density and Lipid Changes During 5 Years of Follow-up in a Study of Prevention of Breast Cancer with Toremifene in Healthy, High-risk Pre- and Post-menopausal Women (2005) (17)
Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer. (1983) (17)
Detection of bone metastases in patients with breast cancer. (1982) (17)
Measurement of S-phase fraction and ploidy in sequential fine-needle aspirates from primary human breast tumours treated with tamoxifen. (1994) (16)
The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factor-beta 1 in metastatic human breast cancer: an immunocytochemical study. (1994) (16)
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. (2007) (16)
Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer (2004) (16)
Treatment of breast cancer with aromatase inhibitors--current status and future prospects. (1989) (16)
The role of aromatase inhibitors in breast cancer. (1983) (15)
Extended adjuvant tamoxifen for breast cancer—a new era? (2013) (15)
Anti-oestrogenic chemoprevention of breast cancer-the need to progress. (2003) (15)
Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer (2004) (14)
High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer. (1986) (14)
Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer. (1985) (14)
Status of antiestrogen breast cancer prevention trials. (1998) (14)
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer. (1993) (13)
Response of metastatic breast cancer to combination chemotherapy according to site. (1977) (13)
The Royal Marsden Hospital (RMH) Trial (2001) (12)
Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women. (1990) (12)
Evaluation of biochemical markers in breast cancer. (1977) (12)
Tests for detecting recurrent disease in the follow-up of patients with breast cancer (1988) (12)
The treatment of postmenopausal women with advanced breast cancer with buserelin (2004) (12)
Trilostane therapy for advanced breast cancer. (1985) (12)
Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer. (1990) (11)
Clodronate: the potential for the future. (1991) (11)
Mitozantrone‐induced onycholysis. A series of five cases (1995) (11)
BENIGN BREAST LESIONS AND OSTEOLYSIS (1976) (11)
Tamoxifen and oestrogen replacement (1990) (11)
Chemotherapy-induced onycholysis. (1996) (11)
Carcinoembryonic antigen estimation in cerebrospinal fluid in patients with metastatic breast cancer. (1981) (11)
Breast cancer : sharing the decision (1999) (11)
Flurbiprofen, a non-steroid anti-inflammatory agent, protects cells against hypoxic cell radiosensitizers in vitro. (1981) (11)
Adjuvant therapy for early breast cancer: a time to refine. (1997) (10)
Endometriosis during tamoxifen treatment (1994) (10)
In vitro osteolytic activity of human breast carcinoma tissue and prognosis. (1981) (10)
Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: Results from the Continuing Outcomes Relevant to Evista (CORE) trial. (2004) (10)
Phase I study of TNFalpha AutoVaccIne in patients with metastatic cancer. (2005) (9)
Advanced breast cancer--new approaches to treatment: a review. (1988) (9)
Mithramycin therapy : an adjunct to conventional treatment of hypercalcaemia and bone metastases in breast cancer (1980) (9)
A comparision of grey-scale ultrasound with other methods for the detection of liver metastases from breast carcinoma. (1976) (8)
Clodronate. (2020) (8)
Anti-metastatic effect of aspirin. (1973) (8)
Chemoprevention of breast cancer. (1989) (8)
Weight loss during therapy for advanced breast cancer. (1982) (8)
Failure to detect intra-abdominal metastases from breast cancer: a case for staging laparotomy (1978) (8)
Case report: Magnetic resonance imaging of spinal amyloid (1989) (8)
Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer (2004) (8)
Differing Perspectives on Breast Cancer Chemoprevention. (2016) (8)
Prevention of breast cancer using SERMs. (2008) (8)
Letter: Mithramycin for hypercalcaemia associated with myeloma and other malignancies. (1975) (8)
anti-oestrogenic prevention of breast cancer — the make or break point (2002) (8)
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. (1995) (8)
Use of erythropoietin in the management of the haemolytic uraemic syndrome induced by mitomycin C/tamoxifen. (1994) (8)
Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. (1983) (8)
[Double-blind trial of oral clodronate in breast cancer patients with bone metastases]. (1993) (7)
Calcium metabolism in breast cancer. (1977) (7)
Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women. (2009) (7)
Using a database of protocol studies to evaluate therapy: a breast cancer example. (1984) (7)
Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials. (2001) (7)
Combination chemotherapy for thrombocytopenia with bone marrow metastases from breast cancer. (1977) (7)
Prostaglandins and cancer : first international conference : proceedings of the First International Conference on Prostaglandins and Cancer, Washington, D.C., August 30-September 2, 1981 (1982) (7)
Premarin in the management of metastatic breast carcinoma in post-menopausal patients. (1979) (6)
A feasibility trial of tamoxifen chemoprevention of breast cancer in Great Britain. (1988) (6)
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment (2005) (6)
Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy (2004) (6)
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial (2017) (6)
Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry (2004) (6)
Age and prognosis in breast cancer. (1979) (6)
A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer. (1986) (6)
Endometrial cancer during tamoxifen treatment. (1994) (6)
TREATMENT OF MENOPAUSAL SYMPTOMS IN BREAST CANCER PATIENTS (1988) (6)
Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assessment: Results of the Continuing Outcomes Relevant to Evista (CORE) trial. (2004) (6)
A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study. (1980) (6)
Aromatase activity, serum oestradiol and their correlation with demographic indices (1992) (5)
Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital experience (1999) (5)
Mitomycin C, melphalan and methotrexate combination chemotherapy for palliation of disseminated breast cancer (2004) (5)
Agents affecting osteolysis in patients with breast cancer (2004) (5)
Fatal irreversible hypercalcaemia in breast cancer. (1977) (5)
Prognostic impact of amenorrhoea after adjuvant chemotherapy. (1998) (5)
Prevention of breast cancer. (1991) (5)
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. (1982) (5)
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials (2016) (4)
SEX HORMONE BINDING GLOBULIN LEVELS AND PROGNOSIS IN EARLY BREAST CANCER (1981) (4)
Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. (1999) (4)
A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma. (1980) (4)
Oncogene Products and Other Diagnostic Markers in Human Breast Cancer Patients (1996) (4)
Oral clodronate maintains bone mass in women with primary breast cancer (2005) (4)
Re: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. (2000) (4)
II.1 Tamoxifen's oestrogen-like effects in a breast cancer chemoprevention trial (1998) (4)
Vindesine in the treatment of breast cancer (2004) (4)
Commentary Isoflavones and women's health (2004) (4)
Chemoprevention of breast cancer: Why is tamoxifen not the answer? (1997) (4)
Nucleoside excretion in breast cancer: comparison with other biochemical tumour-index-substances. (1979) (4)
The value of sequential marker estimations following mastectomy for breast cancer. (1980) (3)
Prevention of breast cancer by newer SERMs in the future. (2011) (3)
A randomised trial of adjuvant versus neoadjuvant endocrine chemotherapy of operable breast cancer (1993) (3)
RESPONSE: Re: Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene (2005) (3)
Magnetic resonance imaging of spinal amyloid. (1989) (3)
Chemoprevention of breast cancer using tamoxifen (1997) (3)
Clubbing, arthralgia and haemoptysis in a patient with metastatic carcinoma of the breast. (1996) (3)
Tumour-induced osteolysis. (1973) (3)
Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials. (2014) (3)
Evolving clinical strategies: innovative approaches to the use of mitoxantrone--introduction. (1997) (3)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer (2009) (3)
Mechanisms for the development of bone metastases and hypercalcaemia in patients with breast cancer. (1977) (3)
Effects of Arzoxifene on Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Mass. (2009) (3)
653 Changes in proliferation in primary breast cancers during chemoendocrine therapy (1995) (3)
Unproven Efficacy of Low-Dose Bisphosphonates as a Means of Decreasing Bone Metastases and Death in Early Breast Cancer. (2018) (3)
Optimal Use of Adjuvant Bisphosphonates and Breast Cancer. (2017) (3)
Endocrine Prevention of Breast Cancer by Tamoxifen (1987) (3)
In vitro osteolysis by human breast tumours. (1977) (2)
Current controversies in cancer tamoxifen for breast cancer prevention (2000) (2)
Fibreoptic bronchoscopy as an aid to diagnosis of respiratory symptoms in breast cancer patients. (1983) (2)
Treatment of advanced breast cancer with miconazole: a potential inhibitor of peripheral oestrogen synthesis. (1991) (2)
The Detection and Evaluation of Bone Marrow Micrometastases in Primary Breast Cancer (1987) (2)
Gene expression arrays for the prediction of response to doxorubicin and cyclophosphamide (AC) in human breast cancers (2005) (2)
668 P53 Mutation and chemosensitivity in breast cancer patients (1995) (2)
Clodronate in Hypercalcaemia and Osteolytic Bone Disease due to Breast Cancer (1993) (2)
The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer (2004) (2)
Breast cancer chemoprevention - Quo vadis? (2001) (2)
Session 5 S15. Tamoxifen and familial breast cancer (2002) (2)
Failure of short-term treatment with flurbiprofen to enhance the therapeutic effect of cyclophosphamide against rodent sarcomas and a leukaemia. (1982) (2)
Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. (1976) (2)
Letter: Tumor-induced osteolysis. (1974) (1)
Danazol treatment for advanced breast cancer. (1983) (1)
Prevention of breast cancer using selective oestrogen receptor modulators (SERMs) (2006) (1)
Prostaglandins and Cancer: Clinical Approaches (1987) (1)
Leukaemic infiltration or primary carcinoma of the breast in a patient with acute myeloid leukaemia (1997) (1)
Speaker against: are we ready to use tamoxifen to prevent breast cancer in daily practice? (1999) (1)
Tumour Markers (1977) (1)
Aminoglutethimide in the management of advanced breast cancer. (1980) (1)
Vindesine as a single agent and in combination with adriamycin in the treatment of metastatic breast carcinoma. (1980) (1)
Screening of inherited breast cancer with DNA markers (1993) (1)
A survey of the opinions on ‘informed consent’ of women attending a breast unit (1993) (1)
A Control Randomised Trial Comparing Vindesine and Adriamycin with Vincristine and Adriamycin in the Treatment of Advanced Breast Carcinoma (1981) (1)
S12 Five year results of a randomised placebo controlled trial of lasofoxifene (PEARL) on the incidence of ER positive breast cancer in postmenopausal women with osteoporosis (2009) (1)
The management of women with a high risk of breast cancer (1996) (1)
New Approaches to the Use of Endocrine Therapy in Breast Cancer (1984) (1)
Serum markers for primary and recurrent breast cancer: BCM-EIA, CAM 26 and CAM 29. (1992) (1)
CHEMOTHERAPY AND SURVIVAL IN BREAST CANCER (1980) (1)
0033 Effects of 5 years of treatment with lasofoxifene on incidence of breast cancer in older women by baseline estradiol levels (2009) (1)
MYELOSUPPRESSION AFTER METHOTREXATE, MITOZANTRONE, AND MITOMYCIN C COMBINATION CHEMOTHERAPY (1987) (1)
Endocrine prevention of breast cancer (2006) (1)
Current controversies in the endocrine therapy of advanced breast cancer. (1992) (1)
Oral clodronate (Bonefos) in women with primary breast cancer: effects on bone turnover and skeletal metastases (2006) (1)
Excision of solitary lung metastases from two patients with breast cancer (1987) (1)
Breast cancer prevention (1999) (1)
90280993 Prevention of breast cancer with tamoxifen - an update on the Royal Marsden Hospital Pilot Programme (1991) (1)
A clinical study of nafazatrom in advanced human breast cancer (2004) (1)
Mitomycin C used in combination withmitoxantrone and methotrexate as first-line cytotoxic treatmentof disseminated breast cancer. (1987) (1)
P106 A Number-Needed-to-Treat(NNT) analysis of bonerelapse and mortality in a randomized trial of oral clodronate as supplementary adjuvant therapy for operable breast cancer (2005) (0)
Use of Selective Antiestrogens for the Chemoprevention of Breast Cancer (2002) (0)
The effect of oral clodronate on bone minerai density in women with primary breast cancer (1997) (0)
Chemoprevention Breast Cancer Workshop, November 20, 1987 Panel Discussions (1988) (0)
Addressing concerns about breast cancer prevention - The Vogel article reviewed (2008) (0)
GENERAL REVIEW POSTMENOPAUSAL ESTROGEN SYNTHESIS AND METABOLISM: ALTERATIONS CAUSED BY AROMATASE INHIBITORS USED FOR THE TREATMENT OF BREAST CANCER (1990) (0)
Session 6 Primary prevention of breast cancer II: Update of chemoprevention with tamoxifen, raloxifen and aromatase-inhibitors (2004) (0)
Tamoxifen and familial breast Cancer (2002) (0)
Response of breast carcinoma to chemotherapy using dynamic MR mammography: Preliminary observations. (1997) (0)
Tamoxifen f or t he P revention o f B reast C ancer: Psychosocial I mpact o n W omen P articipating i n T wo Randomized C ontrolled T rials (2001) (0)
246 Treatment of disseminated breast cancer with multiple hormone therapy using tamoxifen, danazol, aminoglutethimide and hydrocortisone (1983) (0)
Selective oestrogen receptor modulators (SERMs) for prevention of breast cancer. (2013) (0)
Author/Subject Indexes (1992) (0)
Sequential flow cytometry as a method of predicting response and relapse to primary medical therapy in breast cancer (1992) (0)
Commentary (Powles): Improvements in Tumor Targeting, Survivorship, and Chemoprevention Pioneered by Tamoxifen (2006) (0)
Letter to the editors (2004) (0)
"Tamoxifen and Bone: Data From Breast Cancer Prevention Studies" (1998) (0)
Letter: Tranquilizers causing aggression. (1975) (0)
re: Evidence for metastases to a single axillary lymph node from two separate primary breast carcinomas (1998) (0)
Effects of Tamoxifen on Bone (1998) (0)
Practical Considerations in Bone Metastases in Breast Cancer (2005) (0)
Do we have a clinically useful breast cancer risk reduction agent for healthy women? (2006) (0)
Use of Tamoxifen Plus Estrogen (1998) (0)
418 Anti-metastatic efficacy of clodronate is associated with a decrease in bone turnover (2003) (0)
Hypercalciemia in Malignant Disease (1977) (0)
Clodronate Decreases Skeletal Morbidity in Patients with Bone Metastases from Breast Cancer: A Double-Blind Randomised Controlled Trial (1994) (0)
MULTIMODAL THERAPY FOR STAGE-II BREAST CANCER (1978) (0)
687 Oestrogen receptor and K167 status in breast carcinomas following primary chemoendocrine therapy (1995) (0)
AMINOGLUTETHIMIDE IN BREAST CANCER (1978) (0)
Is raloxifene ready to be used for prevention of breast cancer? (2006) (0)
Addressing Concerns About Breast Cancer Prevention (2008) (0)
The Jordan article reviewed (2006) (0)
Comment on: Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor-Targeted Therapy. Authors' reply (2007) (0)
Letter: Benign breast lesions and osteolysis. (1976) (0)
Impact of a panel of 88 SNPs on the risk of breast cancer in high risk women: Results from two randomised tamoxifen prevention trials (2016) (0)
Interactions of cytotoxic and anti-inflammatory agents on normal and neoplastic tissue. (1980) (0)
Administration of prostaglandins A and E and antiinflammatory drugs to patients with cancer. (1983) (0)
Contents, Supplement 1, 1993 (1993) (0)
57 Mitoxantrone and methotrexate (2M), a new chemotherapy regimen for breast cancer that can be safely combined with tamoxifen (1995) (0)
Prostaglandins and Cancer — Therapeutic Potential (1984) (0)
Adjuvant treatment in breast cancer. (1992) (0)
Chemoprevention of beast cancer — An update of the Royal Marsden tamoxifen trial (1992) (0)
Adjuvant therapy for primary breast cancer. (1981) (0)
BMD at diagnosis of primary operable breast doesn't influence the incidence of skeletal metastases. (2001) (0)
52 Rates of local recurrence with neoadjuvant chemoendocrine therapy for primary breast cancer (1995) (0)
Editor's page (2005) (0)
The role of chemoprevention in breast cancer (2004) (0)
Points: Latissimus dorsi reconstruction of the breast (1983) (0)
American S ociety o f C linical O ncology T echnology A ssessment Working G roup U pdate: U se o f A romatase I nhibitors i n t he Adjuvant S etting (2003) (0)
The in-vitro detection of the calcium-mobilising properties of mammary carcinoma. (1973) (0)
Contents, Supplement 2, 1992 (1992) (0)
Hypercalciemia in Malignant Disease (1977) (0)
S19 Prevention of breast cancer by newer SERMs and the future (2010) (0)
EFFECTS OF TAMOXIFEN ON UTERUS. AUTHORS' REPLY (1994) (0)
368 Effect of oral clodronate in women with recurrent breast cancer in the absence of skeletal metastases (1995) (0)
Adjuvant aminoglutethimide for post-menopausal women with primary breast cancer: Analysis of eight years (1992) (0)
377 Therapeutic effects of the aromatase inhibitor fadrozole (F) hydrochloride in advanced breast cancer (1995) (0)
Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer. (1980) (0)
Comment on: continuing outcomes relevant to evista : Breast cancer incidence in post menopausal osteoporotic women in a randomized trial of raloxifene. Authors' reply (2005) (0)
Response to letter "Analysis of breast cancer survival by clinical response to neoadjuvant chemoendocrine therapy" by Bogaerts et al. (Ann Oncol 2006; 17: 352-353). (2006) (0)
Letter: Antiemetics, prolactin, and breast cancer. (1974) (0)
The Production of Osteolytic Substances by Human Breast Tumours (1976) (0)
Responses: Re: Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor-Targeted Therapy (2007) (0)
984 Chemoprevention of breast cancer with tamoxifen (1995) (0)
Hypercalciemia in Malignant Disease (1977) (0)
Screening of inherited breast cancer with DNA markers. (1993) (0)
Combination of the aromatase inhibitors 4-hydroxyandrostenedione (40HA) and aminogluthethimide (AG): An approach to maximization of aromatase inhibition and E2 suppression? (1992) (0)
Treatment of Metastatic Breast Cancer as a Guide to Design of Adjuvant Therapy Trials (1987) (0)
92131613 Aromatase activity, serum oestradiol and their correlation with demographic indices (1992) (0)
ORAL CONTRACEPTIVES AND BREAST CANCER (1984) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Trevor J. Powles?

Trevor J. Powles is affiliated with the following schools:

Trevor J. Powles's Academic­Influence.com Rankings

Trevor J. Powles's Degrees

Why Is Trevor J. Powles Influential?

Trevor J. Powles's Published Works

Published Works

What Schools Are Affiliated With Trevor J. Powles?

Trevor J. Powles's AcademicInfluence.com Rankings